EMMA Emmaus Life Sciences Inc (QB)

(Check One):  ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR

For Period Ended: March 31, 2020
☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
☐ Transition Report on Form N-SAR
For the Transition Period Ended: ___________________

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: ________________________________________________________________________

PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

PART III -- NARRATIVE

State below in reasonable detail why Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, and restatement of the audited financial statements could not be filed within the prescribed time period.

As indicated in a Form 12b-25 filed on May 15, 2020, Emmaus Life Sciences, Inc. (“we,” “us,” “our” and the “company”) was unable to file by the May 14, 2020 filing deadline our Annual Report on Form 10-K for the year ended December 31, 2019, because we need additional time to evaluate the appropriate accounting for certain financial transactions referred to therein. Accordingly, we also were unable to file our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 when due on May 15, 2020.

PART IV-- OTHER INFORMATION

(1) Name and telephone number of the person to contact in regard to this notification.

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  ☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Emmaus Life Sciences (QB) (USOTC:EMMA)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Emmaus Life Sciences (QB) (USOTC:EMMA)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025